A股異動丨金字火腿漲5.65% “人造肉”國標將出台
格隆匯1月7日丨金字火腿(002515.SZ)漲5.65%,報6.55元,總市值64億元。

中國食品科學技術協會主辦的“2019年食品安全與健康熱點科學解讀”的交流會上,中國肉類食品綜合研究中心主任王守偉對熱詞“人造肉”進行相關解讀,表示“人造肉”是未來食品的標誌性產品,具有極大的商業化潛力,加大科技投入是行業未來發力的重要方向。此外,他還透露出,“人造植物肉”國標正在制定中,國標制定有利於規範、培育市場,也是影響資本投資的重大因子。金字火腿生產的人造肉產品目前已在金字火腿天貓旗艦店銷售。本款人造肉產品為牛肉味植物肉餅,以非轉基因大豆等植物蛋白製成,由金字火腿與美國杜邦公司技術合作生產。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.